Press Release

Statement regarding European Commission’s Proposal to Purchase Additional Doses of BioNTech-Pfizer Vaccine

We are in talks with the European Commission (EC) about an amendment to our existing supply agreement for COMIRNATY®, the Pfizer-BioNTech COVID-19 Vaccine. 

The amendment being discussed is for a firm order for an additional 200 million doses of COMIRNATY® to be supplied to the 27 EU member states, with an option for the EC to request an additional 100 million doses.  This amendment would add to the 300 million doses that have already been committed to the EU through 2021 under the original supply agreement signed last year.

The additional doses would be delivered starting in the second quarter of 2021. This would bring the total number of doses to be delivered to EU member states by the end of 2021 to 500 million doses, with the potential for an additional 100 million if the option is exercised. The substance of the ongoing conversations or any further details from them remain confidential.